ArriVent BioPharma, Inc. cash flow to debt ratio of -1.15M% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

ArriVent BioPharma, Inc.'s free cash flow has decreased 128.72% from $-70.21M last year to $-160.59M, signaling decreasing performance

ArriVent BioPharma, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

ArriVent BioPharma, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

ArriVent BioPharma, Inc. has a net cash position, so leverage is healthy.

ArriVent BioPharma, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

ArriVent BioPharma, Inc. has insufficient data to evaluate this check.

ArriVent BioPharma, Inc.'s short-term assets of $332.90M exceed its short-term liabilities of $25.95M

ArriVent BioPharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

ArriVent BioPharma, Inc.'s return on equity of -48.98%, is lower than 15.00%, indicating bad performance

ArriVent BioPharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ArriVent BioPharma, Inc. has insufficient public price history to evaluate earnings stability.

ArriVent BioPharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

ArriVent BioPharma, Inc. has negative free cash flow, indicating cash burn

ArriVent BioPharma, Inc.'s yearly earnings has decreased 106.62% since last year from $-80.49M to $-166.31M, signaling decreasing performance

ArriVent BioPharma, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -48.36% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

ArriVent BioPharma, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

ArriVent BioPharma, Inc. has insufficient public price history to evaluate revenue consistency.

ArriVent BioPharma, Inc. has insufficient public price history to evaluate ROE consistency.

ArriVent BioPharma, Inc. has insufficient data to evaluate this check.

ArriVent BioPharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ArriVent BioPharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

ArriVent BioPharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

ArriVent BioPharma, Inc. has insufficient data to evaluate this check.

ArriVent BioPharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ArriVent BioPharma, Inc. has a price-to-book ratio of 4.31x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

ArriVent BioPharma, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue